Neutralization of SARS-CoV-2 Omicron After Vaccination of Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2022 Mar 28

PMID 35344579

Authors

Lorenza Bellusci

Gabrielle Grubbs

Pragya Srivastava

Michael J Nemeth

Elizabeth A Griffiths

Hana Golding

Surender Khurana

Affiliations

Soon will be listed here.

Citing Articles

Longitudinal Study of SARS-CoV-2 Vaccinations and Infections in Patients with Gastrointestinal Cancer: Stabilizing Immune Responses and Neutralizing Emerging Variants with Variant-Adapted Antigen Exposures.

Gonzalez-Carmona M, Schmitz A, Berger M, Baier L, Gorny J, Sadeghlar F Int J Mol Sci. 2025; 25(24.

PMID: 39769379 PMC: 11728159. DOI: 10.3390/ijms252413613.

Severe COVID-19 in Vaccinated Adults With Hematologic Cancers in the Veterans Health Administration.

Anand S, Vo A, La J, Do N, Fillmore N, Brophy M JAMA Netw Open. 2024; 7(2):e240288.

PMID: 38393725 PMC: 10891464. DOI: 10.1001/jamanetworkopen.2024.0288.

COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches.

Kakavandi S, Hajikhani B, Azizi P, Aziziyan F, Nabi-Afjadi M, Farani M Cell Commun Signal. 2024; 22(1):126.

PMID: 38360719 PMC: 10868124. DOI: 10.1186/s12964-023-01316-9.

Multi-omics analysis of mucosal and systemic immunity to SARS-CoV-2 after birth.

Wimmers F, Burrell A, Feng Y, Zheng H, Arunachalam P, Hu M Cell. 2023; 186(21):4632-4651.e23.

PMID: 37776858 PMC: 10724861. DOI: 10.1016/j.cell.2023.08.044.

Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy.

Reynolds G, Hall V, Teh B Transpl Infect Dis. 2023; 25 Suppl 1:e14109.

PMID: 37515788 PMC: 10909447. DOI: 10.1111/tid.14109.

References

Mori A, Onozawa M, Tsukamoto S, Ishio T, Yokoyama E, Izumiyama K . Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies. Br J Haematol. 2022; 197(6):691-696. PMC: 9111452. DOI: 10.1111/bjh.18138. View

Landtblom A, Andersson T, Dickman P, Smedby K, Eloranta S, Batyrbekova N . Risk of infections in patients with myeloproliferative neoplasms-a population-based cohort study of 8363 patients. Leukemia. 2020; 35(2):476-484. PMC: 7738400. DOI: 10.1038/s41375-020-0909-7. View

B Gilbert P, Montefiori D, McDermott A, Fong Y, Benkeser D, Deng W . Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2021; 375(6576):43-50. PMC: 9017870. DOI: 10.1126/science.abm3425. View

Pagano L, Caira M . Risks for infection in patients with myelodysplasia and acute leukemia. Curr Opin Infect Dis. 2012; 25(6):612-8. DOI: 10.1097/QCO.0b013e328358b000. View

Dayyani F, Conley A, Strom S, Stevenson W, Cortes J, Borthakur G . Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010; 116(9):2174-9. PMC: 3753205. DOI: 10.1002/cncr.24984. View

Sakatoku K, Takeoka Y, Miura A, Araki T, Fujitani Y, Yamamura R . Combination of Frailty Status and Comorbidity Score Improves the Stratification of Survival in Patients With Myelodysplastic Syndrome Owing to Good Predictive Capability for Infection-related Mortality. Clin Lymphoma Myeloma Leuk. 2019; 19(12):799-805. DOI: 10.1016/j.clml.2019.09.610. View

Vijenthira A, Gong I, Fox T, Booth S, Cook G, Fattizzo B . Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020; 136(25):2881-2892. PMC: 7746126. DOI: 10.1182/blood.2020008824. View

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz M . BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021; 384(15):1412-1423. PMC: 7944975. DOI: 10.1056/NEJMoa2101765. View

Trubiano J, Dickinson M, Thursky K, Spelman T, Seymour J, Slavin M . Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes. Leuk Lymphoma. 2017; 58(10):2379-2386. DOI: 10.1080/10428194.2017.1295141. View

10.

Ghione P, Gu J, Attwood K, Torka P, Goel S, Sundaram S . Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies. Blood. 2021; 138(9):811-814. PMC: 8245303. DOI: 10.1182/blood.2021012443. View

11.

Li Z, Philip M, Ferrell P . Alterations of T-cell-mediated immunity in acute myeloid leukemia. Oncogene. 2020; 39(18):3611-3619. PMC: 7234277. DOI: 10.1038/s41388-020-1239-y. View

12.

Mittelman M, Magen O, Barda N, Dagan N, Oster H, Leader A . Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting. Blood. 2021; 139(10):1439-1451. PMC: 8526123. DOI: 10.1182/blood.2021013768. View

13.

Tang J, Lee Y, Ravichandran S, Grubbs G, Huang C, Stauft C . Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern. iScience. 2021; 24(9):103006. PMC: 8378063. DOI: 10.1016/j.isci.2021.103006. View

14.

Khoury D, Cromer D, Reynaldi A, Schlub T, Wheatley A, Juno J . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(7):1205-1211. DOI: 10.1038/s41591-021-01377-8. View

15.

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

16.

Griffiths E, Segal B . Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution. Cancer Cell. 2021; 39(8):1045-1047. PMC: 8253695. DOI: 10.1016/j.ccell.2021.07.001. View